Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring
As Company Pens Nationwide Agreement-In-Principle To Settle US Opioid Claims
Executive Summary
A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.
You may also be interested in...
Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business
Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.
Walgreens And CVS Agree To Opioid Settlements, But States Waiting To See Details
As states weigh their options, the history of past settlements will be a factor. One state signed onto the settlement with the distributors but opted out of the deal with J&J, netting it millions more, and with faster payment, than it would have received under the national settlement.
Finance Watch: Third Harmonic Attempts A Flight Through The IPO Window
Public Company Edition: Third Harmonic hopes to double its money, raising up to $150m. Also, Halozyme priced a $625m note sale to retire debt and repurchase shares, while Viridian raised $270m in an offering after positive early data, and Clarus cut jobs while Endo finalized a restructuring plan.